NCT02519062View on ClinicalTrials.gov

Role of FDG PET, Immune and Hypoxic Marker in NSCLC

CompletedOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
OTHER

No intervention

This is a retrospective study

Trial Locations (1)

20089

Istituto Clinico Humanitas, Rozzano

All Listed Sponsors
lead

Istituto Clinico Humanitas

OTHER

NCT02519062 - Role of FDG PET, Immune and Hypoxic Marker in NSCLC | Biotech Hunter | Biotech Hunter